Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment of First Patients in Phase 1/2a Clinical Trial of its Lead Anticancer Drug MM-D37K - Action News 5 - Memphis, Tennessee

Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment of First Patients in Phase 1/2a Clinical Trial of its Lead Anticancer Drug MM-D37K

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE “MetaMax” LLC

MOSCOW, July 21, 2014 /PRNewswire/ --

The first patients have been enrolled in a Phase 1/2a clinical trial of a promising approach to treat malignant neoplasms. Following approval by the Russian Ministry of Health, Russian biotechnology company MetaMax will begin the trial of its lead anticancer compound MM-D37K. MetaMax is financed by Maxwell Biotech Venture Fund, set up with the participation of RVC. The trial will enroll 21 patients with advanced solid malignancies, including glioblastoma and gastrointestinal tumors.

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/71400589-maxwell-metamax-clinical-trial-anticancer-drug

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b )

     (Logo: http://photos.prnewswire.com/prnh/20140721/697504 )

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-c )

The clinical trial of MM-D37K is being conducted at some of the major Russian oncology centers with a strong 1/2a Phase cancer clinical trials background. The main goal of the trial is to investigate safety, tolerability and pharmacokinetics of multiple use of the study drug in different dose levels, to assess the tumor response to the therapy. Additionally the trial will evaluate the correlation of the therapeutic effect with biomarker levels to select patient populations for further clinical trials of MM-D37K.

Vladimir Bozhenko, Scientific Advisor of MetaMax says "Inhibition of cyclin-dependent kinase 4/6 is one of the most promising approaches in treatment of malignant diseases. This is due to the fact that tumor cells frequently lose the endogenous inhibitors of cyclin-dependent kinases. This leads to an uncontrolled division of the cells. We hope that MM-D37K, by means of recovering the lost functions, will activate the controlled death of the tumor cells, and prevent metastasing to other organs."

About the company "MetaMax" LLC 

"MetaMax" LLC is a private biotech company founded in 2010 to develop innovative biopharmaceutical drugs targeting the most prevalent and dangerous systemic diseases. In August 2011, Metamax became a resident of Biomedical Cluster of the "Skolkovo" Innovation Center and in October joined the participants of Technology Platform "Medicine of the Future". MM-D37K is a lead compound developed by the company. It is the first product of a technology platform based on cell-penetrating peptides and amino acid sequences derived from cyclin-dependent kinases (CDK). One functional part of the peptide MM-D37K is the sequence of endogenous intracellular peptide p16, inhibitor of cyclin-dependent kinases (CDK). The loss of CDK inhibitory function is typical for a broad range of malignant diseases.

Preclinical studies results demonstrated a good safety profile of the peptide and its significant antitumor effect in animal cancer models.

Contact:
Larisa Plekhova, CEO
Office: +7(495)726-5253
e-mail: info@metamax.biz

 


Video: 
     http://www.multivu.com/mnr/71400589-maxwell-metamax-clinical-trial-anticancer-drug

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow